<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BISOPROLOL FUMARATE</span><br/>(bis-o-pro'lol fum'a-rate)<br/><span class="topboxtradename">Zebeta<br/></span><b>Classifications:</b> <span class="classification"> autonomic nervous system agent</span>; <span class="classification">beta-adrenergic antagonist (blocking agent)</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Propranolol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Long-acting cardioselective (beta<sub>1</sub>) adrenoreceptor blocking agent without membrane-stabilizing activity or intrinsic sympathomimetic activity. To maintain beta<sub>1</sub> cardioselectivity, the lowest effective dose is necessary. The mechanism of antihypertensive activity has not been completely
         established. Bisoprolol decreases heart rate, blood pressure, contractile force, and cardiac workload, which reduces myocardial
         oxygen consumption and increases blood flow to myocardium.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Bisoprolol has antianginal properties, especially improving exercise tolerance. Factors affecting hypertension may include
         decreased cardiac output, suppressed renin activity, and decreased sympathetic stimulation from vasomotor centers in the brain.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hypertension.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Angina.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to bisoprolol, severe sinus bradycardia, second- and third-degree AV block, overt cardiac failure,
         cardiogenic shock.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Asthma or COPD, peripheral vascular disease, diabetes mellitus, hyperthyroidism, renal or hepatic insufficiency, pregnancy
         (category C), lactation, anesthetic use.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension, Angina</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.55 mg once daily, may increase to 20 mg/d if necessary<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>
            				Note: The half life of the drug is increased in those with significant liver dysfunction; usual initial dose is 2.5 mg and may be
            carefully titrated upward if necessary.
            			
         </li>
<li>Discontinue drug gradually over a period of 12 wk to avoid rebound, withdrawal angina, or hypertension.</li>
<li>Store at room temperature, 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, fatigue, tiredness, vertigo, anxiety, headache, sleep disturbances. <span class="typehead">CV:</span>  Bradycardia, orthostatic hypotension, rebound/withdrawal angina or hypertension following abrupt discontinuation, may exacerbate
      intermittent claudication. <span class="typehead">Endocrine:</span> Increases serum levels of VLDL-C and decreases levels of HDL-C lipoproteins, may cause slight rise in serum potassium. <span class="typehead">GI:</span> Abdominal pain, dyspepsia, nausea, vomiting, constipation, diarrhea. <span class="typehead"> Respiratory:</span> Asthma, bronchospasm, cough, dyspnea, pharyngitis, sinusitis. <span class="typehead">Skin:</span> Rash, acne, pruritus, eczema. <span class="typehead">Other:</span> Arthralgia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Amiodarone</b> may cause significant bradycardia; <span class="classification">beta blockers</span> may reduce <b>glucose</b> tolerance, inhibit <b>insulin</b> secretion, alter rate of recovery from hypoglycemia, produce hypertension, reduce peripheral circulation, and suppress hypoglycemic
      symptoms; <b>rifampin</b> decreases bisoprolol blood levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; 8294% reaches systemic circulation. <span class="typehead">Peak:</span> Therapeutic effect 24 wk. <span class="typehead">Duration:</span> 24 h. <span class="typehead">Distribution:</span> Some CNS penetration. <span class="typehead">Metabolism:</span> 50% metabolized in liver to inactive metabolites. <span class="typehead">Elimination:</span> 5060% excreted unchanged in urine. <span class="typehead">Half-Life:</span> 1012.4 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness. Time required to achieve optimum antihypertensive effect varies from a few days to
            several weeks.
         </li>
<li>Monitor BP frequently during periods of dose adjustment or drug withdrawal.</li>
<li>Monitor for activity-induced angina both during therapy and following discontinuation of drug.</li>
<li>Monitor for and report severe hypotension and bradycardia. Dosage adjustment may be required.</li>
<li>Monitor for bronchospasms in patients with a history of asthma or COPD.</li>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Lab tests: Periodic CBC, electrolytes, renal function, liver function, lipid profile.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report orthostatic hypotension and dizziness to physician.</li>
<li>Do not discontinue drug abruptly unless specifically instructed to do so.</li>
<li>
            							Note: Drug-induced nightmares and unpleasant dreams are possible when taking this drug.
            						
         </li>
<li>Monitor blood glucose for loss of glycemic control.</li>
<li>Report cold extremities and development of symptoms of intermittent claudication to physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>